Health Canada approves obesity drug Wegovy
The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds ...
But for a long time China’s people struggled to get hold of Wegovy because the country’s regulators had not approved it. Some ...
1don MSN
Few companies garner as much reliable attention as Novo Nordisk ( NVO) does these days. With a bull market coinciding with a ...
About 42% of U.S. adults are obese, the CDC says. GLP-1 medications have changed the picture for people hoping to reduce ...
Novo Nordisk faces challenges in weight-loss sector, but acquisition and strong diabetes portfolio position it for future ...
According to Reuters and CNN, Novo Nordisk announced Monday that it has launched its popular obesity drug Wegovy in China, ...
Patients in China will be able to purchase the blockbuster weight-loss drug Wegovy for 1,400 yuan, or about $193, just a ...
Novo Nordisk's Wegovy launch in China begins in Shanghai at $194 per four-injection pack, significantly cheaper than ...
Novo Nordisk gained approval for Wegovy in China in June, and will initially target Chinese patients willing to pay ...
Novo Nordisk stock has been pretty volatile lately, making it hard to judge whether now is a good opportunity to buy shares.
Novo Nordisk A/S is cutting back on recruiting in Denmark after reaching the limits of its home country’s labor market in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback